Drug Profile
TPI 926
Alternative Names: TPI-926Latest Information Update: 14 Jan 2008
Price :
$50
*
At a glance
- Originator TransForm Pharmaceuticals
- Class Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 11 Apr 2005 TransForm Pharmaceuticals has been acquired by Johnson and Johnson
- 18 Nov 2004 TPI 926 is available for licensing outside the US(http://www.transformpharma.com)
- 15 Nov 2004 Phase-II clinical trials in CNS disorders in Europe (unspecified route)